Know which kind of medicine is being offered.

What compounding means

Compounding means making a medicine to order instead of using a finished product from a drug maker.

It can address a need that an approved product cannot, such as a problem with a particular ingredient.

As of September 26, 2026, FDA approval did not cover compounded preparations.

Before the preparation was marketed, the FDA had not checked how well it worked, its quality, or its safety.

Why old shortage offers need a fresh look

A national drug shortage once opened a route for making copies of tirzepatide.

As of September 26, 2026, tirzepatide was absent from the FDA’s national shortage list.

After the national shortage ended, the FDA gave medicine makers extra time before enforcing the rules that limit copies. That extra time ended in February 2025 for pharmacies making medicine for named patients and March 2025 for larger batch-making sites.

An outsourcing facility is a registered site that makes batches of sterile medicine; sterile means free of living germs.

A local out-of-stock notice does not create a national shortage listing.

Ask about the reason for a compound.

As of September 26, 2026, pharmacists and doctors making medicine for named patients could not regularly make copies of medicines already sold by drug makers.

The law allowed a change that the prescriber judged would make an important difference for a named patient.

That difference could not be based solely on a lower price.

Ask what your own medical need is, what change meets it, and who will make the preparation.

A generic is an FDA-approved version of a brand-name medicine; a made-to-order medicine is different.

No FDA-approved generic tirzepatide existed as of September 26, 2026, so a compound called generic is a reason to pause.

Keep the product explanation alongside the written cost quote.